Did A Special Protocol Assessment Actually Hurt Debiovision’s Sanvar?

FDA’s Gastrointestinal Drugs Advisory Committee concludes that flaws in the trial designed with FDA made it impossible to determine the efficacy of the drug for acute bleeding resulting from portal hypertension.